Lyell

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024
SAN, TIL, AACR, Memory, Abstract, Tumor microenvironment, Patient, Poster, Lyell, Lymphocyte, Vaccine

One oral and two poster presentations will highlight data from Lyell’s product pipeline and research programs, including:

Key Points: 
  • One oral and two poster presentations will highlight data from Lyell’s product pipeline and research programs, including:
    A poster presentation of nonclinical data on LYL119, Lyell’s second-generation ROR1-targeted CAR T-cell product candidate
    Details on the presentations are below.
  • Previously published studies have demonstrated the decline in T-cell function as a person ages.
  • IL-12 is an immune-stimulatory cytokine that can induce potent anti-tumor activity, but unregulated systemic delivery of IL-12 has been shown to have a limited therapeutic window.
  • trIL-12 is being advanced under a collaboration between Lyell and Outpace with the goal of improving efficacy for T-cell therapies by harnessing the therapeutic potential of IL-12.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Wednesday, February 28, 2024
NSCLC, Research, Gene, GSK, TIL, SITC, Growth, AP-1 transcription factor, Cell, International Society, NR4A3, Annual general meeting, Lung cancer, Society, Triple-negative breast cancer, GAAP, Biomarker, Phenotype, TNBC, Patient, Organization, Survival, TCR, Lyell, GSK plc, ISSCR, G&A, Literature, Workforce, IND, Corporation, Colorectal cancer, Vaccine

The study includes patients with relapsed or refractory triple-negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC).

Key Points: 
  • The study includes patients with relapsed or refractory triple-negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC).
  • The increase in fourth quarter 2023 non-GAAP R&D expenses was driven by an increase in research and laboratory costs primarily associated with clinical trials.
  • The decrease in both fourth quarter 2023 and annual 2023 G&A expenses were both primarily driven by decreases in non-cash stock-based compensation.
  • The decrease in 2023 non-GAAP G&A expenses was driven by a decrease in legal and corporate expenses.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Retrieved on: 
Tuesday, November 7, 2023
Science, Research, NR4A3, CAR, NSCLC, IND, Literature, Colorectal cancer, ROR1, G&A, Workforce, GSK plc, GAAP, Phenotype, TIL, R, Lyell, TNBC, SITC, Immunotherapy, Clinical trial, Wine Cellar Innovations, Abstract, GSK, Triple-negative breast cancer, Lung cancer, Society, Patient, Pharmaceutical industry, Vaccine, Medical imaging

An approximately 25% reduction in workforce associated with this prioritization is expected to be completed in the fourth quarter of 2023.

Key Points: 
  • An approximately 25% reduction in workforce associated with this prioritization is expected to be completed in the fourth quarter of 2023.
  • Lyell is advancing four wholly-owned product candidates with two product candidates in Phase 1 clinical development, LYL797 and LYL845.
  • Non‑GAAP G&A expenses, which exclude non-cash stock-based compensation, for the third quarter ended September 30, 2023, were $9.5 million, compared to $11.4 million for the same period in 2022.
  • The decrease in third quarter 2023 non-GAAP G&A expenses was driven by a decrease in legal, consulting and other administrative expenses.

Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing

Retrieved on: 
Tuesday, October 31, 2023
CAR, NSCLC, Innovation, Partial, TCR, Colorectal cancer, Phenotype, Literature, TIL, Lyell, TNBC, SITC, Immunotherapy, Triple-negative breast cancer, Lung cancer, Society, Emerging technologies, Patient, Toxicity, SAN, Vaccine, Medical imaging

“We also highlight new data on our Epi-R P2 manufacturing process, a manufacturing innovation designed to enable faster delivery of TIL product to patients without sacrificing the desired yield, stemness phenotype and retention of tumor reactive clones.”

Key Points: 
  • “We also highlight new data on our Epi-R P2 manufacturing process, a manufacturing innovation designed to enable faster delivery of TIL product to patients without sacrificing the desired yield, stemness phenotype and retention of tumor reactive clones.”
    Details on the presentations are below.
  • Lyell’s Epi-R manufacturing protocols are designed to generate populations of TIL with stem-like properties to potentially improve antitumor activity.
  • Epi-R P2 is an improved TIL manufacturing process that reduces the TIL culture duration to less than three weeks without impacting the quality of TIL.
  • These new nonclinical data show TIL rejuvenated with Lyell’s technology retain a broad TCR repertoire and demonstrate improved T-cell function and antitumor properties.

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Triple-negative breast cancer, Abstract, TNBC, Society, TIL, SITC, Immunotherapy, Lyell, NSCLC, Lung cancer, CAR, Patient, SAN, EPI, Pharmaceutical industry, Medical imaging, Vaccine

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that six abstracts highlighting its broad pipeline of clinical and preclinical product candidates as well as a shortened TIL manufacturing process have been accepted for presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in San Diego, Nov. 1-5, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that six abstracts highlighting its broad pipeline of clinical and preclinical product candidates as well as a shortened TIL manufacturing process have been accepted for presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in San Diego, Nov. 1-5, 2023.
  • “Our presentations at SITC highlight the progress we are making on several fronts to advance new product candidates and technologies designed to generate potent and durable cell therapies for patients with solid tumors,” stated Dr. Gary Lee, chief scientific officer at Lyell.
  • Two additional presentations highlight the design of Lyell’s ongoing Phase 1 clinical trials in progress: LYL797, a ROR1-targeted CAR T-cell therapy being evaluated in a Phase 1 trial in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer, and LYL845, a tumor infiltrating lymphocyte (TIL) therapy being evaluated in a Phase 1 trial in advanced solid tumors.
  • Details on the six poster presentations are below:
    Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies
    Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
    Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors

Shareholder Update: DEEP GREEN Seeing Growth Driven by $2M Nashville Asbestos Project and Strategic Expansion

Retrieved on: 
Tuesday, September 26, 2023
Location identifier, Disposal, DEEP, Transport, Lead, Vanderbilt University Medical Center, Lyell, Conduct, Recycling, Decontamination, Vanderbilt, Documentation, Asbestos, Water, OTC, HEPA, Growth, Environment, Safety, Renewable energy, Demolition, Environmental remediation

"Additionally, DEEP GREEN continues to deliver profitable growth driven by our strategic expansion efforts."

Key Points: 
  • "Additionally, DEEP GREEN continues to deliver profitable growth driven by our strategic expansion efforts."
  • The safe removal of asbestos requires extensive planning and meticulous execution using specialized equipment and techniques.
  • A standard asbestos abatement project will involve the following key phases and tasks:
    Site Evaluation and Planning - Thoroughly survey the site to identify all asbestos-containing materials.
  • DEEP GREEN provides sustainable waste and recycling services to commercial clients, now augmented by full-service remediation capabilities in asbestos, lead, mold and more.

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform

Retrieved on: 
Monday, September 11, 2023
GMP, Triple-negative breast cancer, TAP, Immunotherapy, Lung cancer, CAR, Patient, SAN, Cell, Integrated development environment, SDM, Automation, ROR1, Mobile phone, Vaccine, Lyell, Zasmidium cellare

Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell Immunopharma (NASDAQ: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.

Key Points: 
  • Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell Immunopharma (NASDAQ: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.
  • As part of the collaboration, the companies have agreed on a proof-of-concept technology transfer process for the manufacture of Lyell’s LYL797 CAR T-cell therapy, using the Cell Shuttle.
  • Cellares' innovative manufacturing technology transforms autologous and allogeneic cell therapy processes, covering nearly 90% of cell therapy modalities.
  • Through their TAP program, Cellares can facilitate the automation and tech transfer of manual processes onto the Cell Shuttle manufacturing platform in just six months.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Retrieved on: 
Tuesday, August 8, 2023
GSK, GSK plc, TIL, ISSCR, Clinical trial, Lyell, G&A, GAAP, Research, Biomarker, Lung cancer, NR4A3, Organization, CAR, Patient, Colorectal cancer, SAN, Corporation, Annual general meeting, Growth, CAR T cell, R, International Society for Stem Cell Research, IND, International Society, ROR1, Pharmaceutical industry, Management, Vaccine, Medical imaging

Lyell reported a net loss of $63.9 million for the second quarter ended June 30, 2023, compared to a net loss of $36.3 million for the same period in 2022.

Key Points: 
  • Lyell reported a net loss of $63.9 million for the second quarter ended June 30, 2023, compared to a net loss of $36.3 million for the same period in 2022.
  • Revenue was approximately zero for the second quarter ended June 30, 2023, compared to $35.7 million for the same period in 2022.
  • The decrease in second quarter 2023 G&A expenses was primarily driven by changes in non-cash stock-based compensation.
  • The decrease in second quarter 2023 non-GAAP G&A expenses was driven by a decrease in legal, consulting and other administrative expenses.

Carmot Therapeutics Appoints Charles W. Newton to Board of Directors

Retrieved on: 
Wednesday, July 19, 2023
Newton, Morgan Stanley, Tuck School of Business, BS, Obesity, Diabetes, Lehman Brothers, BofA Securities, MBA, Dartmouth College, Credit Suisse, Miami University, DSM-IV codes, Patient, Growth, Bank, Therapy, Pharmaceutical industry, Philosopher's stone, Finance, Lyell

BERKELEY, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today announced that it has appointed Charles “Charlie” Newton to its Board of Directors.

Key Points: 
  • BERKELEY, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today announced that it has appointed Charles “Charlie” Newton to its Board of Directors.
  • “It’s with great pleasure that we welcome Charlie to the Carmot Board of Directors—we look forward to his guidance as we navigate the exciting opportunities that lie ahead,” said Heather Turner, CEO of Carmot Therapeutics.
  • Mr. Newton commented, "This is an exciting time for Carmot as they advance multiple programs with the goal of treating obesity and diabetes with novel incretin modulators.
  • Mr. Newton earned his MBA from the Tuck School at Dartmouth College as well as a BS in Finance from Miami University.

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

Retrieved on: 
Thursday, July 6, 2023
LSE, Lyell, Cell, Patient, SPL, Cell engineering, Vaccine, Pharmaceutical industry

ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.

Key Points: 
  • Lyell Immunopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in its T cell product candidates targeting solid tumors.
  • ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.
  • Under the terms of the agreement, Lyell Immunopharma obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • In return, MaxCyte is eligible to receive platform licensing fees, clinical milestone payments and sales-based payments.